
Mexican competition watchdog COFECE has identified a company that could have incurred in anti-trust practices in the liquified petroleum gas (LPG) market.
The regulator notified an unspecified player it would start an inquiry into whether the firm had incurred in price discrimination, namely charging different prices for the same product to different customers. The firm participates in the import, distribution and sale of LPG, Cofece said in a release.
If it is found to be in breach, the company could be charged a penalty equal to up to 8% of its revenue.The firm concerned can respond to the accusation and submit evidence to the watchdog in order to defend its practices, which may be upheld through various justifications, including efficiency gains, or other benefits to end consumers. The agency’s plenary will then issue a ruling, in a process that as been known to drag out for several months.
Read More: Mexico’s COFECE Takes On Government Over Energy Policy
Last year, COFECE issued a report stating the country’s LPG market lacked appropriate competition conditions and could require additional regulations. It also accused several companies of forming an oligopoly aimed at divvying up the market to avoid competing with each other.
Earlier this year, Cofece engaged in an industry debate regarding changes proposed by the energy ministry and natural gas grid control center Cenace that would force private players to contract natural gas from state-owned companies to access transport capacity in national gas system Sistrangas.
Cofece said the measure would “compromise non-discriminatory open access to the system … artificially strengthening the position of the state-owned firms and sidelining private gas sellers.”
Watch: CPI TV Ten Minutes With COFECE President Alejandra Palacios
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas